Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
- Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T
- Builds on long-standing relationship between the two companies
- In Japan around 90,000 new cases of prostate cancer are diagnosed each year
PARIS, Oct. 01, 2024 (GLOBE NEWSWIRE) - Curium, a world leader in nuclear medicine, announced today that it has entered into a strategic partnership with PDRadiopharma Inc, a wholly-owned subsidiary of PeptiDream, for the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T. The two agents 177Lu-PSMA-I&T and 64Cu-PSMA-I&T target prostate specific membrane antigen (PSMA) expressed on prostate cancer cells and are being investigated for prostate cancer treatment and diagnostics. Both target tumors with high levels of PSMA expression and thus potentially forming a theranostic (therapeutic & diagnostic) pair.
Under the terms of the partnership, Curium and PDRadiopharma will jointly collaborate on clinical development activities of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T in Japan, with PDRadiopharma leading regulatory filing, manufacturing, commercialization, and distribution activities in Japan. Curium will continue to lead global development of the two agents and support PDRadiopharma through technology transfer to support the set-up of manufacturing lines in Japan – including a high throughput Copper 64 manufacturing line based on Curium’s proprietary technology.
Patrick C. Reid, President & CEO of PeptiDream commented: “Targeted radiopharmaceuticals are rapidly revolutionizing how we both diagnose and treat cancer. At PeptiDream and PDRadiopharma we are focused on expanding our pipeline of these powerful targeted therapies, and we are thrilled to be able to accelerate those efforts by partnering with Curium to bring their highly promising prostate cancer targeting radiopharmaceuticals to patients in Japan.”
Masato Murakami, President of PDRadiopharma & CMO of PeptiDream commented: “We are excited to partner with Curium in the development of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T, highly promising products for both the diagnosis and treatment of PSMA-expressing prostate cancer. We look forward to working with Curium to deliver these much-needed agents to prostate cancer patients in Japan as quickly as possible.”
Chaitanya Tatineni, Curium’s CEO International Markets commented: “As a global innovator in the field of radiopharmaceuticals with a promising late-stage oncology pipeline, Curium is delighted to partner with PDRadiopharma which has more than four decades of experience in Japan. Curium and PDRadiopharma plan to leverage their complementary strengths to accelerate the development of innovative products for the benefit of prostate cancer patients in Japan.”
Prostate cancer continues to be widely prevalent in Japan. Annually, there are approximately 90,000 – 100,000 new cases, with patients with metastatic castration-resistant prostate cancer having an overall survival rate of approximately three years in clinical trial settings, and even shorter in the real-world, and there remains a significant unmet medical need for therapies.
177Lu-PSMA-I&T, a PSMA inhibitor conjugated with the radioisotope Lutetium 177, is currently being tested by Curium in a global pivotal Phase 3 ECLIPSE trial (ClinicalTrials.gov identifier; NCT05204927). ECLIPSE is a multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer. The ECLIPSE trial enrolled over 400 patients, across 51 trial sites in the United States and Europe.
64Cu-PSMA-I&T PET is currently being investigated in 2 multicenter Phase 3 trials; SOLAR RECUR testing the diagnostic performance in men with biochemical recurrence of prostate cancer (ClinicalTrials.gov identifier NCT06235099) and SOLAR STAGE testing the diagnostic performance in men with newly diagnosed unfavorable intermediate- to high-risk prostate cancer (ClinicalTrials.gov identifier; NCT06235151). The first in human Phase 1/2 SOLAR trial met the co-primary endpoints of region-level correct localization rate and patient-level correct detection rate in patients with histologically-proven metastatic prostate cancer. PSMA-targeted PET/CT imaging is increasingly emerging as a highly sensitive method for detection of locally recurrent or metastatic lesions in the context of biochemical recurrence and for localization of primary prostate cancer.
Curium and PDRadiopharma have a long-standing relationship in the radiopharmaceutical field.
For more information:
PeptiDream Inc.
Yuko Okimoto, IR & Public Affairs
info@peptidream.com
PDRadiopharma Inc.
Noriko Tanaka, General Affairs
s-info-hq@pdradiopharma.com
Curium
Ross Bethell
VP, Head of Global Communications
communications@curiumpharma.com
About PeptiDream Inc.
PeptiDream Inc. (Tokyo Stock Exchange Prime Market 4587) is leading the translation of macrocyclic peptides into a whole new class of innovative medicines to address unmet medical needs and improve the quality of life of patients worldwide. In its radiopharmaceutical business, through its wholly-owned subsidiary PDRadiopharma, PeptiDream markets and sells a number of approved radiopharmaceuticals and radiodiagnostics in Japan, as well as leveraging its proprietary Peptide Discovery Platform System (PDPS) technology to discover and develop a deep pipeline of innovative targeted radiotherapeutics and radiodiagnostics, spanning both wholly-owned internal programs and globally partnered programs. In its non-radiopharmaceutical business, PeptiDream is similarly leveraging PDPS to discover and develop a broad and diverse pipeline of investigational peptide therapeutics, peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki, Japan. For more information about our company, science and pipeline, please visit www.peptidream.com/en
About PDRadiopharma
PDRadiopharma, a wholly-owned subsidiary of PeptiDream since 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field in radiopharmaceuticals, since it started its business in 1968. PDRadiopharma currently markets 21 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit www.pdradiopharma.com/en
About Curium
Curium is a world leader in nuclear medicine. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service. With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit www.curiumpharma.com
- 李梦男新剧《星星的故乡》今晚登陆央视黄金档 成名副其实的“央视脸”
- 关雅荻发文批评某脱口秀节目审核问题:为博流量乱搞事情?
- 《藏海花》开播 孙一理用角色魅力拉开雪域篇章
- 安顺文化旅游2024(南京)推介会在宁成功举办
- 2024山东国际大健康产业博览会·卫生健康事业高质量发展大会成功召开
- 望京之星|与时代共舞,谋定都会商务办公新未来!
- 中信银行太原迎西支行走进阳曲消防队开展“3.15”金融宣讲活动
- 富呗商城璀璨登场,为您带来全新的商业体验!
- 强强联合!微笑时代与河南小白兔口腔正式签署战略合作!
- 大器可成墨海藏龙—黎大墨的艺术人生
- 理大学者研发智能软件机器人防护衣 自动调温隔热 保障高温环境工作安全
- 临商银行金雀山支行开展“金融标准 为民利企”宣传活动
- SC200x系列再添新成员!移远通信智能模组SC200V / SC200U系列正式发布
- 中国平安上半年归母营运利润、中期派息保持稳定,归母净利润同比增6.8% 寿险新业务价值同比增11.0%,高质量发展成效显现
- 618开门红Saramonic枫笛年中直降15%!无线狂欢 枫玩夏天
- IBM:能力出海和企业出海的数字化能力
- 不断释放增长潜力 美菱冰箱热销618
- 玫瑰的故事,在美菱上演
- 碧桂园服务:“借力”新零售 让桃梨芬芳铺就助农振兴路
- 青少年食品安全与营养健康科普教育活动走进南京
- 京东婚庆用品亮相北京婚博会 一站式备婚省心又轻松
- 新城投·御河园获荣誉 演绎新一代好房子
- 【广材试验机】广州+佛山地导线卧式拉力试验机报价/方案/厂家
- Norths Collective利用Boomi为6.1万多名会员提供个性化体验,加速业务扩张
- C.K. McWhorter To Open Conversations With Supreme Council of Antiquities To Protect & Preserve A
- 央心心理咨询携手奥运冠军向艳梅,共筑全民身心灵健康
- 想要孕期好皮肤?轻上100%椰子水喝起来!
- 远光软件:全面财会监督,构筑风险防控的“铜墙铁壁”
- 千寻位置亮相全球数字经济大会,获评“北京市北斗时空信息创新应用典型案例”
- Instagram协议号营销工具,ins精准引流软件,ig群发助手/ins协议号源头
推荐
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 王自如被强制执行3383万 据中国执行信息公开网消息,近期,王自如新增一 资讯
- 抖音直播“新红人”进攻本地生活领域 不难看出,抖音本地生活正借由直播向本地生活 资讯
- 一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
- 男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯